Compare CSBR & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSBR | TIL |
|---|---|---|
| Founded | 1985 | 2018 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.0M | 74.7M |
| IPO Year | N/A | N/A |
| Metric | CSBR | TIL |
|---|---|---|
| Price | $6.03 | $8.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | $12.00 | ★ $125.00 |
| AVG Volume (30 Days) | 6.2K | ★ 69.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.84 | N/A |
| Revenue Next Year | $11.51 | N/A |
| P/E Ratio | $33.52 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.59 | $5.67 |
| 52 Week High | $11.16 | $42.79 |
| Indicator | CSBR | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 36.31 | 59.35 |
| Support Level | $6.53 | $7.51 |
| Resistance Level | $6.34 | $7.87 |
| Average True Range (ATR) | 0.39 | 0.41 |
| MACD | -0.13 | 0.27 |
| Stochastic Oscillator | 6.07 | 91.03 |
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.